Research programme: anthracyclines - Galilaeus Oy

Drug Profile

Research programme: anthracyclines - Galilaeus Oy

Alternative Names: Research programme: anticancer therapeutics - Galilaeus Oy/Heidelberg Pharma Research; S 2512; S 2513

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galilaeus Oy
  • Developer Heidelberg Pharma
  • Class Anthracyclines
  • Mechanism of Action DNA inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 15 May 2003 S 2513 and S 2521 are available for licensing (
  • 15 May 2003 Preclinical trials in Cancer in Finland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top